To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

rhPDGF-BB (Augment) is a safe alternative to autologous graft in foot and ankle fusion

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
March 2013

rhPDGF-BB (Augment) is a safe alternative to autologous graft in foot and ankle fusion

Vol: 2| Issue: 2| Number:72| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Prospective, Randomized, Multi-Center Feasibility Trial of rhPDGF-BB Versus Autologous Bone Graft in a Foot and Ankle Fusion Model

Foot Ankle Int. 2011 Apr;32(4):344-54.

Contributing Authors:
CW Digiovanni J Baumhauer SS Lin WS Berberian AS Flemister MJ Enna P Evangelista J Newman

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

20 patients requiring hindfoot fusion were randomized to receive either a biosynthetic bone graft substitute (Augment Bone Graft, a recombinant form of platelet-derived growth factor (rhPDGF-BB)) or an autologous bone graft (ABG), in order to compare safety and efficacy between the two graft types. The results of this study suggest the biosynthetic bone graft is a safe and efficacious alternative ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue